FTFinancial Times·1hBusiness
score-0.50
AstraZeneca Investors Scrutinize $400bn Bristol Myers Squibb Merger Talks Amid Patent and Antitrust Questions
Original
AstraZeneca investors raise concerns over mega-merger talks
“Headline emphasizes investor anxiety, patent cliffs, and regulatory risks, framing the merger as a high-stakes threat rather than an opportunity.”